Targeted delivery in primary and metastatic brain tumors: Summary report of the seventh annual meeting of the blood-brain barrier disruption consortium

Nancy Doolittle, Lauren E. Abrey, Nicolay Ferrari, Walter A. Hall, Edward R. Laws, Roger E. McLendon, Leslie Muldoon, David Peereboom, Darryl R. Peterson, C. Patrick Reynolds, Peter Senter, Edward Neuwelt

Research output: Contribution to journalArticle

17 Scopus citations


The November 2000 NIH report of the Brain Tumor Progress Review Group identified delivering and targeting therapeutic agents as a priority in the treatment of malignant brain tumors. For this reason, the seventh annual Blood-Brain Barrier Disruption Consortium meeting, partially funded by an NIH R13 Grant, focused on recent advances in targeted delivery to the central nervous system, clinical trials for primary and metastatic brain tumors using enhanced chemotherapy delivery, and strategies to lessen the toxicities associated with dose intensive treatments, using thiols.

Original languageEnglish (US)
Pages (from-to)1702-1709
Number of pages8
JournalClinical Cancer Research
Issue number6
Publication statusPublished - 2002


ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this